MedTrace Logo

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

NCT00944736 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-03-10

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of a probiotic formulation, VSL#3, on intestinal permeability in pediatric patients with Crohn's disease.

Conditions

Interventions

DIETARY_SUPPLEMENT

VSL#3

1 packet BID

DIETARY_SUPPLEMENT

Placebo

1 inactive packet BID

Sponsors & Collaborators

  • VSL Pharmaceuticals

    collaborator INDUSTRY

  • Children's Mercy Hospital Kansas City

    lead OTHER

Principal Investigators

  • Julia M Bracken, MD · Children's Mercy Hospital Kansas City

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00944736 on ClinicalTrials.gov